Clearmind Medicine (NASDAQ:CMND) Major Shareholder Acquires $323,857.80 in Stock

Posted by Stanley Muller on Jun 15th, 2026

Clearmind Medicine Inc. (NASDAQ:CMND – Get Free Report) major shareholder Financial Lp Hrt bought 2,159,052 shares of the business’s stock in a transaction that occurred on Wednesday, June 10th. The stock was acquired at an average cost of $0.15 per share, for a total transaction of $323,857.80. Following the completion of the purchase, the insider directly owned 2,063,266 shares of the company’s stock, valued at $309,489.90. The trade was a -2,254.04% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

On Thursday, June 11th, Financial Lp Hrt sold 225,191 shares of Clearmind Medicine stock. The stock was sold at an average price of $0.12, for a total value of $27,022.92.

Clearmind Medicine Price Performance

NASDAQ CMND opened at $3.34 on Monday. The stock has a market capitalization of $3.41 million, a PE ratio of -0.02 and a beta of 0.65. Clearmind Medicine Inc. has a 1 year low of $2.10 and a 1 year high of $524.00. The business’s 50-day moving average is $6.22 and its 200 day moving average is $16.48.

Clearmind Medicine (NASDAQ:CMND – Get Free Report) last posted its earnings results on Thursday, March 12th. The company reported ($33.20) earnings per share (EPS) for the quarter.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded shares of Clearmind Medicine to a “sell” rating in a report on Saturday, May 23rd.

Check Out Our Latest Analysis on CMND

Clearmind Medicine Company Profile

(Get Free Report)

Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.

Clearmind’s pipeline includes multiple preclinical and early clinical candidates.